Detection rate of ¹⁸F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: Results from a phase 3, prospective, multicenter study (SPOTLIGHT)

David M. Schuster

PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of ¹⁷⁷Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).

James Patrick Buteau

PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Fred Saad

Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair

Kim N. Chi

Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.

Matthew Raymond Smith

A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) pl

Axel S. Merseburger

Identifying patient profiles and mapping the patient journey across three countries in a large-scale, fully digital survey of patients with prostate cancer.

Alicia K. Morgans

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).

Xin Gao

Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).

Karim Fizazi

Bone mineral density in men with <i>de novo</i> metastatic castration-sensitive prostate cancer treated with or without abiraterone plus prednisone in the PEACE-1 phase 3 trial.

Guilhem Roubaud

Prostate-specific antigen (PSA) outcomes in black (B) and white (W) chemotherapy-naïve (CN) prostate cancer (PC) patients (pts) treated with enzalutamide (ENZA).

Alicia K. Morgans

Financial toxicity and its effect on screening for prostate and colon cancer.

Michael Joseph Herriges

Hormonal treatment for newly diagnosed metastatic prostate cancer: A population-based study of 15,435 cases from the California Cancer Registry (2009-2018).

David Joseph Benjamin

Disparities in prostate cancer: An ethnicity comparative focus among Hispanic Americans versus non-Hispanic whites.

Alejandro Recio-Boiles

Comparative ctDNA analyses of African-American and Caucasian patients with CRPC.

Ellen B. Jaeger

A quantitative synthesis of disparities in the inclusion of racial/ethnic minorities and older adults in prostate cancer clinical trials over the last three decades.

Irbaz Bin Riaz

Association between health-care system and prostate cancer mortality for African American men with localized and metastatic prostate cancer.

Tyler J. Nelson

Racial disparity in survival of African-American (AA) patients diagnosed with metastatic prostate cancer: Analysis of surveillance epidemiology and end results program.

Muhammad Zain Farooq

Impact of COVID-19 on the incidence of prostate cancer among White and Black Veterans.

Kyung Min Lee

Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: Estimates from the Centers for Disease Control WONDER database.

Chinmay Jani

Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET: An international multicenter retrospective study.

Masatoshi Hotta

Predictive factors for effectiveness from novel androgen-receptor-axis-targeted agents in patients with metastatic prostate cancer.

Koshiro Nishimoto

Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer.

Dongxu Qiu

Piflufolastat F 18-PET/CT in prostate cancer patients: An analysis of OSPREY (Cohorts A and B) standardized uptake value (SUV) results stratified by PSA and gleason score.

Michael A. Gorin

Kinetics of PSMA PET uptake in prostate cancer lesions after radiation therapy: A single-center retrospective study.

Masatoshi Hotta

68 Ga-PSMA PET/CT for preoperative lymph nosde staging of high-risk prostate cancer.

Axel Heidenreich

First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.

Iris S. H. Kloots

Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP): An international multicenter study.

Andrei Gafita

Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide.

Benjamin Lowentritt

Practice patterns in the management of metastatic castration-sensitive prostate cancer: A single-center survey-based study.

Eric Lu

Factors associated with gene mutation testing in United States veterans with metastatic castration-resistant prostate cancer.

Anna Hung

Real-world treatment patterns among patients with metastatic castration-resistant prostate cancer (mCRPC) in the US.

Elisabetta Malangone-Monaco

Statin type and survival of patients with metastatic castrate-resistant prostate cancer receiving abiraterone and enzalutamide: A nationwide retrospective cohort study.

Harrison S. Yoon

Impact of U.S. Preventative Services Task Force grade D recommendation against prostate-specific antigen screening on prostate cancer mortality.

Laura Burgess

Treatment (tx) patterns among men with metastatic castration resistant prostate cancer (mCRPC) in the United States (US).

Pedro C. Barata

Patterns of care for patients with non-metastatic castration-resistant prostate cancer: Population-based study in Ontario, Canada.

Shawn Malone

Real-world health-related quality of life and caregiver need in patients with metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.

Mark Boye

Use of bone modifying agents for metastatic castrate-resistant prostate cancer.

Aaron Philip Mitchell

Evaluating the contribution of virtual peer-led support to comprehensive prostate cancer (PCa) care: The AnCan experience.

Herbert M. Geller

Impact of provider education on prostate cancer genetic counseling referrals.

Emily Moody

Treatment outcomes for metastatic castration-resistant prostate cancer (mCRPC) following progression on upfront androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPI) for metastatic castration-sensitive prostate cancer (mCSPC)

Daniel Joseph Khalaf

Baseline parameters of patients with prostate cancer (PCa) initiating a triptorelin treatment for at least 12 months in real life, TALISMAN study interim analysis.

Antoine Thiery-Vuillemin

Preliminary results of the "DUO" observational study: Quality of life assessment and cross-sectional follow-up of prostate cancer patients treated with degarelix.

Morgan Roupret

Preferences and perceptions of patients with metastatic castration-resistant prostate cancer for treatments and biomarker testing: An international qualitative study.

Robert J. Jones

Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.

Niamh M. Keegan

Prevalence and natural history of non-metastatic castrate resistant prostate cancer: A population-based analysis.

Amanda Elizabeth Hird

Treatment trends among men with metastatic castration sensitive prostate cancer (mCSPC): Results from the US component of an international study.

Pedro C. Barata

The changing landscape of treatment and survival for men with castration-resistant prostate cancer in the era of novel treatments.

Megan Veresh Caram

Impact of pretest video genetic education in prostate cancer patients: Do patients need us?

Samantha Greenberg

First look at patient reported outcomes from IRONMAN, the international registry of men with advanced prostate cancer.

Emily Rencsok

Correlation of the rate of metastasis-free survival with the presence of pathogenic germline genetic mutations in patients with prostate cancer at a community practice.

Siddharth Ramanathan

Diagnosis codes overestimate the burden of prostate cancer cases.

Tori Anglin-Foote

Association between patient-reported outcomes (PROs) and changes in prostate-specific antigen (PSA) in patients (pts) with advanced prostate cancer treated with apalutamide (APA) in the SPARTAN and TITAN studies.

Eric Jay Small

The effects of a preference-based exercise trial on outcomes in men on androgen deprivation therapy (ADT) for prostate cancer compared to an exercise randomized controlled trial of the same interventions.

Shabbir M.H. Alibhai

Electronic patient reporting outcomes are a promising predictive factor of prostate cancer patient survival: The Protecty study.

Carole Helissey

Assessment of patient-reported outcomes (PROs) and longer-term adverse events (AEs) in phase I study of ²²⁵Ac-J591-PSMA for metastatic castration-resistant prostate cancer (mCRPC).

Jones T. Nauseef

Association of functional outcomes by decision-making approach in men with metastatic prostate cancer (mPC).

Frank Schumacher

A prospective study of the relationship between CRPC patient's quality of life after enzalutamide and serum testosterone levels measured via LC-MS/MS.

Yoshiyuki Miyazawa

Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: A US survey.

Daniel J. George

Characteristics of prostate cancer survivors exposed to ADT and enrolled in a fall prevention exercise trial: Comparison of men with confirmed fall history to men with fall risk factors.

Kerri M. Winters-Stone

Daily symptom monitoring commonly leads to treatment modification in older adults receiving treatment for metastatic prostate cancer (mPC).

Henriette Breunis

Statin use and survival in men receiving androgen-ablative therapies for advanced prostate cancer: A systematic review and meta-analysis of cohort studies.

Viranda Helitha Jayalath

A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer.

David James VanderWeele

Exposure-adjusted safety analyses of the VISION phase 3 trial of ¹⁷⁷Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Kim N. Chi

Evolving real-world patterns of practice in metastatic castration-sensitive prostate cancer (mCSPC): The genitourinary research consortium (GURC) national multicenter cohort study.

Steven Yip

DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A subgroup analysis of a phase 1/2 multicenter study.

Manish R. Patel

Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).

Zachery R Reichert

The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.

Kim N. Chi

Long-term safety of darolutamide in patients with metastatic castration-resistant prostate cancer.

Egils Vjaters

Phase 1 study of PSCA-targeted chimeric antigen receptor (CAR) T cell therapy for metastatic castration-resistant prostate cancer (mCRPC).

Tanya B. Dorff

Hospitalizations and common infections among veterans treated for metastatic prostate cancer.

Forest Riekhof

Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer.

Mohammad O. Atiq

Safety and early efficacy results from a phase 1, multicenter trial of PSMA-targeted armored CAR T cells in patients with advanced mCRPC.

Meredith McKean

A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).

David William Pook

Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer.

Brian D. Gonzalez

Dosimetry of ¹⁷⁷Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study.

Ken Herrmann

Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant prostate cancer (mCRPC).

Susan F. Slovin

Randomized controlled trial of GnRH antagonist monotherapy versus GnRH agonist plus bicalutamide (CAB) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) (KYUCOG-1401).

Akira Yokomizo

ARTO trial-(NCT03449719): Early results from a phase II randomized trial testing stereotactic body radiation therapy in patients with oligometastatic castration-resistant prostate cancer undergoing I line treatment with abiraterone acetate.

Giulio Francolini

Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix verus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase 3 HERO study.

Neal D. Shore

PSA-progression only in high-risk, metastatatic hormone-sensitive prostate cancer patients treated with abiraterone in the LATITUDE trial.

David Lorente

Phase 2 trial of immunotherapy in tumors with CDK12 inactivation (IMPACT): Results from cohort A of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) receiving dual immune checkpoint inhibition (ICI).

Ajjai Shivaram Alva

Testosterone recovery for relugolix versus leuprolide in men with advanced prostate cancer: Results from the phase 3 HERO study.

Ronald F. Tutrone

Efficacy and safety of relugolix in black men with advanced prostate cancer: A subgroup analysis from the randomized, phase 3 HERO study versus leuprolide.

Daniel J. George

Cohort study of oligorecurrent prostate cancer patients: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery.

Tobias Maurer

Patterns of progression of patients with high-volume metastatic castration-sensitive prostate cancer treated with early docetaxel chemotherapy: The LONGITUDE observational study.

Serena Macrini

Updated overall survival (OS) analysis for ProCAID: A randomized, doubleblind, placebo-controlled phase II trial of capivasertib with docetaxel versus docetaxel alone in metastatic castration-sensitive prostate cancer (mCRPC).

Simon J. Crabb

Serial stereotactic body radiation therapy for oligometastatic prostate cancer (PCa) detected by positron emission tomography (PET) imaging.

David Shui

The role of sabizabulin in phase 1b/2 clinical trials of men with metastatic castration-resistant prostate cancer who progressed on androgen receptor-targeting agents.

Mark Christopher Markowski

Evaluation of drug-drug interactions among patients with metastatic prostate cancer in routine care.

Noemie Gassian

Clinical utility of next-generation sequencing for prostate cancer in the context of a changing treatment landscape.

Jacqueline R. Griffin

Treatment outcomes of patients with metastatic prostate cancer and co-morbid diabetes mellitus.

Srinivas Govindan

AbiDex: Retrospective U.K. analysis of steroid switching in patients with progression of mCRPC treated with abiraterone acetate.

Dan Muller

Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) + androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or <i>de novo<

Andrew J. Armstrong

Survival of patients with metastatic prostate cancer and comorbid obesity.

Nina Cheranda

Phase 2 randomized trial of ModraDoc006/r, oral docetaxel plus ritonavir, versus intravenous docetaxel in metastatic castration resistant prostate cancer (mCRPC).

Ulka N. Vaishampayan

Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone (p) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from KEYNOTE-365 cohort D.

Cristiano Ferrario

Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE).

Rana R. McKay

Community oncologists' perceptions of and barriers to access for ¹⁷⁷LUPSMA-617 in metastatic castration-resistant prostate cancer.

Ajeet Gajra

Overall survival (OS) after progression on first novel hormonal therapy (NHT) in patients (pts) with metastatic castration-sensitive versus castration-resistant prostate cancer (mCSPC versus mCRPC).

Nicolas Sayegh

Enzalutamide versus abiraterone plus prednisolone before chemotherapy for Japanese castration-resistant prostate cancer patients: An investigatorinitiated, multicenter, randomized controlled trial.

Kouji Izumi

Survival outcomes and characterization of patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) undergoing intensified androgen deprivation therapy (ADT) who do not achieve an optimal PSA response (PSA ≤0.2 ng/mL).

Nicolas Sayegh

BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype—Phase 2a results.

Jingsong Zhang

BXCL701: First-in-class oral activator of systemic innate immunity combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small-cell neuroendocrine carcinoma (SCNC) phenotype—Phase 2a interim results.

Scott T. Tagawa

The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study.

Luke Meininger

BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Benedito A. Carneiro

DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.

Laura Graham

Evaluating the optimal sequence of immunotherapy and docetaxel in men with metastatic castration-sensitive prostate cancer.

Elias Bin Aris Chandran

Progression-free survival, PFS, depending on the site of lymph-node metastases in patients after salvage lymph node dissection, sLAD, in lymph node only recurrent prostate cancer.

David Pfister

First-line treatment options in metastatic castration-sensitive prostate cancer: A systematic review and network meta-analysis.

Irbaz Bin Riaz

Progression-free survival (PFS) and overall survival (OS) in patients (pts) with de-novo, high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) undergoing intensified androgen deprivation therapy (ADT).

Umang Swami

Differential efficacy of PARP inhibitors in metastatic castration-resistant prostate cancer with DNA repair defects: A systematic review and meta-analysis.

Syed Arsalan Ahmed Naqvi

Third analysis of a randomized trial of finite abiraterone acetate (AA) plus LHRH agonist (LHRHa) versus LHRHa in biochemically recurrent, non-metastatic hormone-naïve prostate cancer (M0HNPC).

Andrew Warren Hahn

Triplet therapy in metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.

Syed Arsalan Ahmed Naqvi

PRIMERA trial (NCT04188275), early survival results from a prospective trial exploring impact of circulating tumor cell detection in castrate resistant prostate cancer patients undergoing abiraterone or enzalutamide I line treatment.

Giulio Francolini

Implications of androgen receptor (AR) alterations identified by genomic testing of tissue and blood from advanced prostate cancer (aPC) patients (pts).

Zeynep Busra Zengin

Association of circulating tumor cell RB1 loss RNA signature with outcomes and immune phenotypes in men with mCRPC.

Jiaren Zhang

<i>HSD3B1</i> polymorphism in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP): Pharmacodynamics and therapeutic implications.

Diogo Assed Bastos

Effect of PSMA-positive membranes secreted from prostate cancer cells on vascular endothelial cells.

Ryuta Watanabe

Blood biomarkers and association with clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC): prespecified longitudinal analysis from the ACIS study of apalutamide (APA) or placebo combined with abiraterone acetate plus prednisone (A

Eleni Efstathiou

Genomic evolution from hormonal therapies and suitability of prostate cancer diagnostic specimens for metastatic prostate cancer (mPC) genomic stratification.

Amado J. Zurita

Germline APC (I1307K) mutation and clinical outcomes in prostate cancer.

Minas P. Economides

Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) +/- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).

Bradley Alexander McGregor

Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.

Elahe A. Mostaghel

Comprehensive genomic profiling unravels molecular targets in patients with metastatic spinal cord compression from prostate cancer.

Tony Duong

Germline <i>BRCA2</i>, <i>ATM</i> and <i>CHEK2</i> alterations shape somatic mutation landscapes in prostate cancer.

Mari Nakazawa

A microRNA-based classifier for identification of neuroendocrine differentiation in metastatic castration-resistant prostate cancer.

Sharanjot Saini

Age-based assessment of cell-free DNA genomic profiles in metastatic castration-resistant prostate cancer (mCRPC).

Andrea Knox

Interrelation of functional homologous recombination deficiency and hrr pathway alterations in prostate cancer.

Jason Zhu

Association of changing bone metastatic (mets) patterns with dynamics of circulating tumor DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC).

Vincenza Conteduca

Prognostic and predictive utility of DNA damage response (DDR) aberrations detected in cell-free DNA (cfDNA) in metastatic castration-resistant prostate cancer (mCRPC).

Heidi Fettke

Modulation of the plasma lipidomic profile with simvastatin in metastatic castration-resistant prostate cancer (mCRPC).

Blossom Mak

Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer in the multi-ancestry Million Veteran Program cohort.

Meghana Pagadala

Association of <i>RB1</i> mutational status with overall genomic landscape in neuroendocrine prostate cancer (NEPC).

Petros Grivas

TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)—Exploration of germline DDR alteration landscape and potential associations with antitumor activity.

Tanya B. Dorff

Body fat composition as biomarker for clinical outcomes and treatment tolerance in high-risk prostate cancer.

Anurag Saraf

Effect of androgen receptor directed therapy in prostate cancer patients with COVID-19.

Serhan Unlu

Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study.

Nicolas Sayegh

Immune profiling of advanced prostate cancer harboring homologous recombination deficiency.

Maryam Soleimani

Blood-based tumor mutational burden from circulating tumor DNA and immune checkpoint inhibitors in advanced prostate cancer.

Grant Rauterkus

Clinical and molecular features of low prostate-specific membrane antigen (PSMA) expression in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

Ivan de Kouchkovsky

ADAM: A multicenter, non-interventional, prospective cohort study for determination of prevalence of homologous recombination repair genes mutations (HRRm) in metastatic castrate-resistant prostate cancer (mCRPC)—Interim analysis.

Boris Alexeev

Molecular testing for prostate cancer in Greek patients.

Michael Liontos

Liquid biopsy <i>AR</i>/enhancer alteration detection before AR-targeted therapy and correlation with survival in metastatic castrate-resistant prostate cancer patients.

Alexander Shiang

Circulating tumor DNA responses to high-dose testosterone injections in CRPC patients.

Sydney Caputo

Lipidomic profiling in patients with heavily pretreated castration-resistant prostate cancer.

Carlo Cattrini

Analysis of the role of PI3K-AKT and DNA damage repair (DDR) genomic biomarkers as predictors of clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC).

Richard Gagnon

Patient derived tumor xenograft study with CDK4/6 inhibitor plus AKT inhibitor for management of metastatic castrate resistant prostate cancer.

Adam McLain Kase

Evaluation of ctDNA alterations in mCRPC patients with germline pathogenic mutations.

Malcolm Light

Frequencies of actionable alterations found by somatic tumor sequencing in veterans with metastatic prostate cancer.

Nicholas George Nickols

Putative germline findings in tumor-only and liquid biopsy sequencing in veterans with aggressive prostate cancer.

Kara Noelle Maxwell

Identification of homologous recombination and repair (HRR) deficiency using circulating tumor DNA (ctDNA) in advanced prostate cancer (aPC).

Leslie A. Bucheit

3JC48-3: Novel MYC inhibition in advanced prostate cancer.

Victor Chalfant

Extracellular vesicle-based assay for detecting metastases and dynamic monitoring of prostate cancer.

Jasmine Jiemei Wang

Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.

Umang Swami

Virtual genetics board for enhancing knowledge and practice of prostate cancer genetic testing: The ENGAGEMENT study.

Veda N. Giri

Genomic characterization of patients (pts) with de-novo high-volume metastatic castration-sensitive prostate cancer (dn-hv-mCSPC) compared to those without dn-hv-mCSPC.

Nicolas Sayegh

Trends in disease burden from prostate cancer amongst different regions of the world and extensively the European Union 15+ countries, from 1990 to 2019: Estimates from the Global Burden of Disease study.

Christian Mouchati

Prevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study.

Veda N. Giri

68ga-PSMA-11 patients with newly diagnosed and recurrent prostate cancer (Firefly).

Charlotte Manogue

IRONMAN: The international registry for men with advanced prostate cancer.

Daniel J. George

PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.

Channing Judith Paller

Different fractionation schedules of radiotherapy to the primary tumor in metastatic hormone sensitive prostate cancer (Hypo-M1).

Camilla Thellenberg-Karlsson

A randomized, controlled trial of group exercise training for fall prevention and functional improvements during and after treatment for prostate cancer.

Kerri M. Winters-Stone

Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo as novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).

Arpit Rao

A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).

Atish Dipankar Choudhury

Evaluation of tumor genomic variants in Japanese patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide: Protocol of a phase 4 study (CUARTET).

Hirotsugu Uemura

Phase 1b study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).

Rahul Raj Aggarwal

CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.

Matthew Raymond Smith

PEARLS: A multicenter phase II/III trial of extended field radiotherapy for androgen-sensitive prostate cancer patients with PSMA-avid pelvic and paraaortic lymph nodes at presentation.

Julia Murray

A randomized, controlled, phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus ADT alone in metastatic hormone-sensitive prostate cancer (ARANOTE).

Haresh KP

A randomized mCRPC phase 2b study of the BET bromodomain inhibitor (BETi) zen-3694 and enzalutamide vesus enzalutamide.

Rahul Raj Aggarwal

Trial in progress: Durvalumab and olaparib for the treatment of prostate cancer in men predicted to have a high neoantigen load.

Alexandra Sokolova

Veterans affairs seamless phase II/III randomized trial of standard systemic therapy with or without PET-directed local therapy for oligorecurrent prostate cancer (VA STARPORT).

Abhishek A Solanki

KEYNOTE-365 cohorts G and H: Phase 1b/2 study of pembrolizumab + vibostolimab combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).

Neal D. Shore

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).

Louise Emmett

Phase 1 study of JNJ-69086420, an actinium-225-labeled antibody targeting human kallikrein-2, for advanced prostate cancer.

Michael J. Morris

Relugolix in combination with abiraterone acetate, apalutamide, or docetaxel in men with advanced prostate cancer (aPC): A phase 1, three-part, open-label, parallel-cohort study.

Jose De La Cerda

A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.

Jonathan Alexander Chatzkel

A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naïve prostate cancer (mHNPC): ZZFIRST.

Joaquin Mateo

PSMAddition: A phase 3 trial to compare treatment with ¹⁷⁷Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer.

A. Oliver Sartor

PSMAfore: A phase 3 study to compare ¹⁷⁷Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer.

A. Oliver Sartor

Salvage radiotherapy (SRT) in combination with pembrolizumab in patients with PSA persistence or biochemical recurrence after radical prostatectomy due to prostate cancer.

Markus Grabbert

A phase II trial of abemaciclib (abema) and atezolizumab (atezo) in unselected and <i>CDK12</i>-loss metastatic castration-resistant prostate cancer (mCRPC).

Arpit Rao

A phase 1b clinical trial of cabozantinib (CABO) and abiraterone (ABI) with checkpoint inhibitor immunotherapy (CPI) in metastatic hormone-sensitive prostate cancer (mHSPC) (CABIOS Trial).

Melissa Andrea Reimers

KEYNOTE-365 cohorts E and F: Phase 1b/2 study of pembrolizumab + lenvatinib combination therapy in patients with adenocarcinoma metastatic castration-resistant prostate cancer (mCRPC) or treatment-emergent neuroendocrine mCRPC (t-NE).

Gero Kramer

Phase I/II trial of pembrolizumab and AR signaling inhibitor +/- 225Ac-J591 for chemo-naive metastatic castration-resistant prostate cancer (mCRPC).

Scott T. Tagawa

Phase 3 VERACITY clinical study of sabizabulin in men with metastatic castrate resistant prostate cancer who have progressed on an androgen receptor targeting agent.

Robert Dreicer

KEYNOTE-365 cohort I: Phase 1b/2 study of pembrolizumab combined with platinum-containing chemotherapy and chemotherapy alone for treatment-emergent neuroendocrine prostate carcinoma (t-NE).

Johann S. De Bono

A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

David Johnson Einstein

A single-arm, open-label, phase 2 study evaluating pacritinib for patients with biochemical recurrence after definitive treatment for prostate cancer: Blast study.

Deepak Kilari

Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC).

Neeraj Agarwal

Development and validation of a prognostic AI biomarker using multi-modal deep learning with digital histopathology in localized prostate cancer on NRG Oncology phase III clinical trials.

Andre Esteva

An AI-derived digital pathology-based biomarker to predict the benefit of androgen deprivation therapy in localized prostate cancer with validation in NRG/RTOG 9408.

Daniel Eidelberg Spratt

Randomized phase II trial of neoadjuvant abiraterone plus or minus cabazitaxel in high-risk prostate cancer: ACDC-RP.

Neil E. Fleshner

Association between prostate-specific antigen screening and prostate cancer mortality in a racially diverse cohort of United States veterans.

Michael Vincent Sherer

Aspartyl (Asparaginyl) β-hydroxylase (AABH) as a serum biomarker for prostate cancer, to identify prostate cancer, regardless of PSA level.

Mahmood Moshiri

Impact of clinical staging based on DRE versus imaging (TRUS/MRI) in localized prostate cancer risk assessment.

Kevin Chang

Preoperative PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.

Benjamin Pockros

MiCheck prostate blood test for aggressive prostate cancer designed for the clinical lab setting.

Neal D. Shore

The BARCODE1 study in primary care: Early results targeting men with increased genetic risk of developing prostate cancer—Examining the interim data from a community-based screening program using polygenic risk score to target screening.

Jana Kathlyn McHugh

Health-related quality of life as a prognostic indicator of biochemical recurrence free survival in high-risk prostate cancer patients following radical prostatectomy.

Thilo Westhofen

Comparative study of RARP and carbon ion radiotherapy sexual functional changes for prostate cancer using the propensity score matching method.

Yoshiyuki Miyazawa

Characteristics of prostate cancer patients captured by facility-based versus geography-based cancer registries.

Christopher Paul Filson

Prostate specific antigen dynamics and prostate cancer risk: A population-based study.

Amanda Elizabeth Hird

Low-value prostate cancer screening among young men with private insurance.

Jeffrey Vehawn

Contemporary outcomes of a systematic prostate cancer active surveillance program: Results from the Niagara Health System, Ontario, Canada.

Aruz Mesci

Outcomes and factors associated with reclassification in a multiethnic cohort enrolled in active surveillance for prostate cancer.

Denzel Zhu

Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: A secondary analysis of the NRG oncology RTOG 0415 randomized clinical trial.

David James Carpenter

Real-world evidence of patient-reported outcomes following definitive radiation therapy for prostate cancer: Findings from an Australian population-based clinical outcomes registry.

Wee Loon Ong

Discordance of patient- and physician-reported toxicities in two prospective trials of stereotactic body radiotherapy (SBRT) for localized prostate cancer.

Akshat Patel

Late, persistent, substantial, treatment-related symptoms (LAPERS) following low-dose-rate brachytherapy for prostate cancer.

Wee Loon Ong

A phase II trial of hypofractionated radiation therapy over five treatments for prostate cancer with high-risk features after radical prostatectomy: MC1754.

Carlos E. Vargas

Immunotherapy to prevent progression on active surveillance study (IPASS): A phase II, randomized, double-blind, controlled trial of PROSTVAC in prostate cancer patients who are candidates for active surveillance.

J Kellogg Parsons

Real-world management of metastatic castration-resistant prostate cancer (mCRPC): A national multicenter cohort study.

Luke Lavallee

Magnetic resonance imaging-guided versus computed tomography-guided stereotactic body radiotherapy for prostate cancer (MIRAGE): Interim analysis of a phase III randomized trial.

Amar Upadhyaya Kishan

Efficacy and safety outcomes of darolutamide in patients with nonmetastatic castration-resistant prostate cancer with comorbidities and concomitant medications from ARAMIS.

Karim Fizazi

A phase I does-escalation and expansion study of epidiolex (cannabidiol) in patients with biochemically recurrent prostate cancer.

Zin Myint

External beam radiation therapy with or without brachytherapy boost for low PSA, high-grade prostate cancer.

Benjamin Walker Fischer-Valuck

Long-term outcomes of a pilot study on highly hypofractionated intensity-modulated radiation therapy over three weeks for localized prostate cancer.

Kiyonao Nakamura

Implementation of PSMA-PET in focal dose-escalated radiotherapy of primary prostate cancer patients: Results of a planned safety analysis of a phase II trial.

Simon K.B. Spohn

Early initiation of salvage radiotherapy is associated with improved metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.

Emerson Lee

High-dose external BEAM intensity-modulated radiotherapy (HD-IMRT) versus intensity-modulated radiotherapy plus HDR brachytherapy boost (LD-IMRT+ HDR-B) dose escalation for intermediate- or high-risk prostate cancer.

Ines Guix

Survival outcomes in men with unfavorable intermediate-risk and high-risk prostate cancer treated with prostate-only versus whole pelvic radiation therapy.

Neal Andruska

Molecular characterization to delineate the clonal evolution of primary prostate cancer with synchronous lymph node metastasis.

Udit Singhal

Transcriptomic discriminators of response to apalutamide in patients with prostate cancer (PC) on active surveillance (AS).

Michael Thomas Schweizer

A genomic classifier for prostate cancer correlates with adverse pathologic features: Transcriptomic features of cribriform and intraductal carcinoma of the prostate.

Zaeem M Lone

Validation of the performance of the Decipher biopsy genomic classifier in intermediate-risk prostate cancer on the phase III randomized trial NRG Oncology/RTOG 0126.

Daniel Eidelberg Spratt

Genomic instability is enriched in localized prostate cancers from men of African ancestry.

Jones T. Nauseef

The role of spatial transcriptomic profiling to determine androgen receptor signaling and immune infiltration in prostate cancer.

Parth Patel

Comparative genomic analyses between Asian and Caucasian prostate cancers in an 80,829 patient cohort.

Adelene Sim Yen Ling

Longitudinal ctDNA alterations in germline positive CRPC patients.

Minqi Huang

Pathologic and radiographic outcomes following prostate cancer diagnosis aided by IsoPSA testing.

Tarik Benidir

Local failure, distant metastasis, and survival after definitive radiotherapy for intermediate- and high-risk prostate cancer: An individual patient-level meta-analysis of 18 randomized trials.

Ting Martin Ma

Safety and preliminary clinical activity of JNJ-63898081 (JNJ-081), a PSMA and CD3 bispecific antibody, for the treatment of metastatic castrate-resistant prostate cancer (mCRPC).

Emerson A. Lim

Comparison of the medical costs between active surveillance and other treatment for early prostate cancer in Japan: From the data of PRIAS JAPAN study.

Takuma Kato

Disease progression and competing mortality for men undergoing active surveillance for low-risk prostate cancer.

Kripa Guram

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-ris

Adam S. Kibel

A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer.

David James VanderWeele

BCG efficacy in nonmuscle-invasive bladder cancer after prior radiation treatment for prostate cancer.

Adri Durant